Acute Rejection in Transplantation

Definition and Timing

  • Acute rejection: A phenomenon occurring within weeks, months, or even years after transplantation; most commonly observed in the first few weeks post-transplant.

    • Damage is primarily caused by T cells and secondary antibodies.

    • The primary target in acute rejection is the human leukocyte antigen (HLA), also known as the major histocompatibility complex (MHC).

Historical Context

  • The term HLA originated from early transplantation experiments, where immune responses were noted against antigens, believed to involve lymphocytes (white blood cells). The designation MHC was subsequently established.

Alloantigens

  • Alloantigen: Refers to antigens that provoke an immune response due to being recognized as foreign (allo means other/foreign).

    • These are specifically targeted by the recipient's immune system against the donor's HLA antigens.

T Cell Recognition Mechanism

  • T cells require presentation of antigens on HLA/MHC molecules for activation.

    • Activation signals for naive T cells consist of three essential signals: Recognition, Co-stimulation, and Cytokines.

    • During thymocyte development, T cells that do not recognize self MHC are eliminated.

HLA Gene Diversity

  • Humans possess a total of six HLA class I and II genes (three of each from both parents).

    • HLA genes exhibit extensive polymorphism—over 20,000 MHC class I alleles exist, making them the most polymorphic loci known.

  • Polygenic nature of HLA: Involves multiple genes encoding similar proteins.

    • Designations for these genes include HLA A, B, C (class I) and HLA DP, DQ, DR (class II).

  • Codominant expression: Both alleles from each parent are expressed simultaneously.

Allo-recognition by T Cells

  • Allo-recognition: Occurs when T cells detect foreign graft HLA antigens as non-self, initiating a robust immune response (stronger than a typical pathogen response).

    • Donor cells express numerous HLA peptide complexes, which intensify T cell activation.

Comparison of Immune Responses

  • Up to 1% of T cells can recognize HLA peptides as foreign, compared to only 0.0001-0.00001% recognizing typical pathogen peptides.

  • Despite T cells being trained in the thymus to recognize self HLA, there is an immune response against foreign HLA peptide complexes in graft tissues received.

Mechanisms of T Cell Activation in Graft Rejection

Direct Allorecognition

  • In this pathway, recipient T cells directly interact with donor HLA and antigens, recognizing the foreign HLA-peptide shape as a pathogenic threat.

    • Components involved:

    • Recipient TCR (T Cell Receptor)

    • Donor DC (Dendritic Cells) presenting foreign HLA peptide

    • Recipient co-stimulatory molecules (e.g., CD28)

  • The interaction of recipient T cells with donor antigens leads to T cell activation and an immune response.

Indirect Allorecognition

  • This mechanism occurs when recipient antigen-presenting cells (APCs) present donor HLA peptides.

    • The process involves:

    • Recipient APC detecting and processing donor peptides, presenting them via self HLA molecules to T cells.

  • This pathway resembles a conventional immune response to pathogens, resulting in sustained immune activity against the graft tissue.

Consequences of Acute Rejection

  • Acute rejection leads to significant graft damage due to the persistent immune response.

  • No elimination of the graft occurs, resulting in a chronically activated immune response.

Strategies to Minimize Acute Rejection

  • Reduce immunogenicity of the graft by:

    • Matching HLA alleles between donor and recipient.

    • Utilizing immunosuppressive drugs targeting T cell activation.

  • Although achieving a 12 out of 12 match (complete HLA match) is ideal, it is often impractical due to diverse allele combinations and geographical limitations.

  • Focusing on matching the most critical three genes (two from HLA class I and one from HLA class II) can improve graft success rates.

Pre-existing Antibodies and Testing

  • About 30% of patients awaiting transplantation possess pre-existing HLA antibodies, which complicates the transplant process.

  • Screening involves assessing patient antibodies against a panel of common HLA antigens using specialized assays with coated beads.

  • Pre-existing antibodies detection is essential before identifying a donor to mitigate potential rejection risks.

Immunosuppressive Strategies

  • Immunosuppression aims to enhance graft survival by inhibiting T cell functions.

  • Various drug agents are tailored to individual needs and are utilized in varied combinations:

    • Calcineurin inhibitors (e.g., tacrolimus) reduce IL-2 production crucial for T cell activity.

    • Anti-proliferative drugs target the cell cycle to minimize T cell proliferation.

  • The usage of multiple immunosuppressive agents allows lower doses and minimizes side effects, balancing rejection prevention with the immunity needed against pathogens.

Side Effects and Trade-offs

  • Generalized immunosuppression leads to risks such as:

    • Life-threatening infections

    • Development of malignancies

  • Finding a balance in immunosuppressive therapy is crucial for patient outcomes.

Conclusion

  • Acute rejection occurs post-transplant due to T cells recognizing graft HLA as foreign, triggering an immune response similar to that against pathogens.

  • Allo-recognition can be either direct (recipient T cells interacting with donor HLA) or indirect (recipient APC presenting donor peptides), encouraging graft damage.

  • Achieving HLA matches minimizes rejection chances, substantiated by immunosuppressive treatments necessary for graft survival despite their inherent risks and side effects.